AlphAIalphai — Financial news for AI agents
BenzingaNOV 32 min read$NMRA

Neumora Therapeutics to Participate in Upcoming Conferences in November - Neumora Therapeutics (NASDAQ:NMRA)

WATERTOWN, Mass., Nov. 03, 2025 ( GLOBE NEWSWIRE ) -- Neumora Therapeutics, Inc. ( NASDAQ:NMRA ) , a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, ...

Original reporting
Benzinga · Globe Newswire
Published Nov 3, 2025, 12:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Nov 4, 2025, 12:32 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Neumora Therapeutics to Participate in Upcoming Conferences in November - Neumora Therapeutics (NASDAQ:NMRA) — source image
Source · www.benzinga.com
Decision brief

The 30-second read

$NMRABullishMed
01

Why it matters

Conference appearances can serve as catalysts for investor interest, potentially influencing stock liquidity and volatility.

02

Market read

The news is relevant primarily to biotech investors and analysts monitoring Neumora's development pipeline and investor engagement activities.

03

What to watch

Potential delays or setbacks in clinical programs that could offset positive conference effects.

Timing: Immediate, as conferences are scheduled for November 2025.

Background

Neumora Therapeutics is a clinical-stage biotech firm with multiple pipeline programs targeting underserved diseases, seeking increased visibility through conference participation.

Company-level read

Ticker impact

$NMRABullishMedium confidence
Context

The news pertains directly to Neumora Therapeutics, Inc. (NASDAQ: NMRA), highlighting upcoming conferences which could influence investor sentiment and trading activity.

Expected impact

Moderate upward movement expected in the short term, contingent on conference outcomes.

Evidence & confidence

While conference participation can boost visibility and investor interest, actual market impact depends on conference results and broader market conditions.

Market effects

Sector

Potential positive impact on biotech sector sentiment due to increased visibility of innovative therapeutics.

Regional

Primarily US-based, with possible ripple effects in global biotech markets.

Global

Limited; primarily relevant to US investors and biotech sector participants.

Counterpoint

What could challenge this read

Conference participation may have minimal impact if broader market conditions are unfavorable or if the company's fundamentals do not support a rally.

Key entities

  • Company
    Neumora Therapeutics, Inc.

    A biopharmaceutical company focused on novel therapeutics for underserved diseases.

  • Event
    Upcoming Conferences in November 2025

    Industry conferences where Neumora will present its pipeline and research updates.

Read at source← All news

Related articles

AUG 14
$NMRAMed

Neumora Therapeutics, Inc.: Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Neumora Therapeutics (Nasdaq: NMRA) reported Q2 2026 results and a pipeline update. It said NMRA-215 IND submission is planned for Q4 2026 with Phase 1 initiation by year end. NMRA-511 AD agitation data are expected in Q4 2026, and NMRA-898 schizophrenia Phase 1 data in 2H 2026. Cash was $116.8M, funding operations into Q3 2027; Q2 net loss was $43.1M.

finanznachrichten.de4 min
AUG 14
$NMRAMed

Neumora Therapeutics, Inc. (NMRA): Results of Operations and Financial Condition

Neumora Therapeutics, Inc. (NMRA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 nmra-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update Favorable pre-clinical data reported for NMRA-215 with plan to submit IND in fourth quarter of 2026 and initiate Phase 1 study by

SEC EDGAR 8-K6 min
JUN 19
$SPROMed

Weekly Buzz: SPRO, ABBV Get FDA Nod, NMRA Halts KOASTAL; ENGN Cuts Jobs; BIIB Acquires RayThera

Biotech news roundup: Spero (SPRO) and GSK won FDA approval for Utebzi (tebipenem pivoxil) for complicated UTIs; AbbVie (ABBV) expanded FDA approval of SKINVIVE by JUVÉDERM to neck lines; Cuprina (CUPR) received 510(k) clearance for MEDIFLY maggots. Neumora (NMRA) halted KOASTAL Phase 3 and plans 35% layoffs; enGene (ENGN) cuts ~50%. Biogen (BIIB) agreed to buy RayThera for up to $1B.

rttnews.com6 min
JUN 16
$NMRAMedAI 8/10

Neumora Therapeutics Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Neumora Therapeutics (NMRA)

Levi & Korsinsky said it has opened an investigation into Neumora Therapeutics’ officers and directors after the company disclosed that navacaprant failed both Phase 3 KOASTAL-2 and KOASTAL-3 trials in major depressive disorder and announced an immediate ~35% workforce reduction. The article notes the stock fell nearly 50% and cites prior company comments during earnings and in January 2026.

prnewswire.com3 min
AUG 18
$XOMMedAI 8/10

ExxonMobil awards $1.1B in Contracts for LNG project

ExxonMobil said it awarded about $1.1 billion in pre-investment contracts for upstream equipment for the Rovuma LNG Phase 1 project in Mozambique’s Cabo Delgado. The awards, made for Area 4 partners including ENH, CNOOC, Eni, Korea Gas and ADNOC, cover subsea production systems, valves and offshore line pipe to support a final investment decision. OneSubsea UK/AS received the largest contract.

oedigital.com4 min